Article info

Original research
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Authors

  1. Correspondence to Dr Jason J Luke; lukejj{at}upmc.edu
View Full Text

Citation

Luke JJ, Barlesi F, Chung K, et al
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Publication history

  • Accepted December 31, 2020
  • First published February 19, 2021.
Online issue publication 
February 19, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.